Skip to main content
GILEAD SCIENCES, INC. logo

GILEAD SCIENCES, INC. — Investor Relations & Filings

Ticker · GILD ISIN · US3755581036 LEI · 549300WTZWR07K8MNV44 US Manufacturing
Open in API
Filings indexed 1,975 across all filing types
Latest filing 2026-05-20 Capital/Financing Update
Country US United States of America
Listing US GILD

About GILEAD SCIENCES, INC.

https://www.gilead.com/

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines to address unmet medical needs. The company's primary focus is on virology, with a portfolio of transformative therapies for life-threatening diseases such as HIV/AIDS and viral hepatitis. Gilead is also expanding its impact in oncology and inflammation, maintaining a diverse pipeline of clinical programs across these key therapeutic areas. The company invests in scientific research to develop treatments for some of the world's most challenging diseases, aiming to improve the lives of patients globally.

Recent filings

Filing Released Lang Actions
FORM 8-K
Capital/Financing Update Classification · 85% confidence The document is a Form 8-K current report detailing the entry into a material definitive agreement and issuance of senior notes (4.250% 2028, 4.400% 2029, 4.600% 2031, 4.900% 2034), along with the related indenture supplements and underwriting agreement. This constitutes an update on the company’s financing activities and changes to its capital structure, matching the Capital/Financing Update category.
2026-05-20 English
424B5
Capital/Financing Update Classification · 89% confidence The document is a Rule 424(b)(5) prospectus supplement for a $3 billion senior notes offering by Gilead Sciences, detailing the terms, underwriters, risk factors, use of proceeds and other offering information. This is a formal financing document describing a debt capital raise and a change in the company’s capital structure. According to the definitions, updates on company fundraising or financing activities fall under Capital/Financing Update (CAP).
2026-05-18 English
FWP
Capital/Financing Update Classification · 85% confidence The document is a Free Writing Prospectus (FWP) pursuant to SEC Rule 433, providing the pricing term sheet for multiple series of senior notes (2028, 2029, 2031 and 2034) issued by Gilead Sciences, Inc. It details principal amounts, interest rates, maturity dates, yields, redemption features, CUSIPs, bookrunners and co-managers. This is clearly announcing a debt financing transaction, fitting the Capital/Financing Update category.
2026-05-14 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a SEC prospectus supplement (Form 424B5) detailing the terms of a new debt securities offering by Gilead Sciences, Inc., including use of proceeds, description of notes, underwriting and related capital structure information. This is not an annual or quarterly report, nor a management discussion, but rather a financing document for a shelf registration debt issuance. It therefore falls under Capital/Financing Update (CAP).
2026-05-14 English
Regulatory Filings 2026
Regulatory Filings
2026-05-08 English
S-8 - GILEAD SCIENCES, INC. (0000882095) (Filer)
Share Issue/Capital Change Classification · 85% confidence The document is a Securities and Exchange Commission registration statement on Form S-8, which registers shares of common stock issuable under the company’s 2022 Equity Incentive Plan. This is not an annual or quarterly report, proxy, or earnings release, but rather a filing to register new share issuance under an employee equity plan. That falls under Share Issue/Capital Change (SHA).
2026-05-07 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.